{"id":"NCT02412787","sponsor":"Shire","briefTitle":"Study of Long Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Participants Who Have Completed Study HGT-HIT-094","officialTitle":"An Open Label Extension of Study HGT-HIT-094 Evaluating Long Term Safety and Clinical Outcomes of Intrathecal Idursulfase Administered in Conjunction With ElapraseÂ® in Patients With Hunter Syndrome and Cognitive Impairment","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2015-04-14","primaryCompletion":"2024-04-18","completion":"2024-04-18","firstPosted":"2015-04-09","resultsPosted":"2025-06-19","lastUpdate":"2025-06-19"},"enrollment":56,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hunter Syndrome"],"interventions":[{"type":"DRUG","name":"Idursulfase-IT","otherNames":["HGT-2310"]},{"type":"DRUG","name":"Elaprase","otherNames":[]}],"arms":[{"label":"Idursulfase-IT","type":"EXPERIMENTAL"}],"summary":"This extension study will allow participants that completed Study HGT-HIT-094 to continue receiving Elaprase treatment in conjunction with idursulfase IT or to continue receiving Elaprase treatment and begin concurrent IT treatment for those that did not receive idursulfase IT treatment in Study HGT-HIT-094.","primaryOutcome":{"measure":"Number of Participants With Adverse Events (AEs)","timeFrame":"Up to 9 years","effectByArm":[{"arm":"Idursulfase-IT","deltaMin":56,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"MALE","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":9,"countries":["United States","Australia","Canada","France","Mexico","Spain","United Kingdom"]},"refs":{"pmids":["37915038","35961250"],"seeAlso":["https://clinicaltrials.takeda.com/study-detail/5f6b5fd54db2bf003ab46df0"]},"adverseEventsSummary":{"seriousAny":{"events":48,"n":56},"commonTop":["Pyrexia","Cough","Vomiting","Nasopharyngitis","Upper respiratory tract infection"]}}